146 related articles for article (PubMed ID: 37746718)
41. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
[TBL] [Abstract][Full Text] [Related]
42. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
Lehmann LH; Cautela J; Palaskas N; Baik AH; Meijers WC; Allenbach Y; Alexandre J; Rassaf T; Müller OJ; Aras M; Asnani AH; Deswal A; Laufer-Perl M; Thuny F; Kerneis M; Hayek SS; Ederhy S; Salem JE; Moslehi JJ
JAMA Cardiol; 2021 Nov; 6(11):1329-1337. PubMed ID: 34232253
[TBL] [Abstract][Full Text] [Related]
43. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
44. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
45. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
46. EBV-positive pyothorax-associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3.
Higuchi T; Hashida Y; Matsuo K; Kitahata K; Ujihara T; Murakami I; Nakayama T; Daibata M
Cancer Sci; 2023 Jun; 114(6):2622-2633. PubMed ID: 36898851
[TBL] [Abstract][Full Text] [Related]
47. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
Thomas MF; Slowikowski K; Manakongtreecheep K; Sen P; Samanta N; Tantivit J; Nasrallah M; Zubiri L; Smith NP; Tirard A; Ramesh S; Arnold BY; Nieman LT; Chen JH; Eisenhaure T; Pelka K; Song Y; Xu KH; Jorgji V; Pinto CJ; Sharova T; Glasser R; Chan P; Sullivan RJ; Khalili H; Juric D; Boland GM; Dougan M; Hacohen N; Li B; Reynolds KL; Villani AC
Nat Med; 2024 May; 30(5):1349-1362. PubMed ID: 38724705
[TBL] [Abstract][Full Text] [Related]
48. The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis.
Abu El-Asrar AM; Struyf S; Al-Kharashi SA; Missotten L; Van Damme J; Geboes K
Am J Ophthalmol; 2003 Nov; 136(5):853-60. PubMed ID: 14597036
[TBL] [Abstract][Full Text] [Related]
49. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.
Zhang Y; Sun C; Li Y; Qin J; Amancherla K; Jing Y; Hu Q; Liang K; Zhang Z; Ye Y; Huang LA; Nguyen TK; Egranov SD; Zhao Z; Wu A; Xi Y; Yao J; Hung MC; Calin GA; Cheng J; Lim B; Lehmann LH; Salem JE; Johnson DB; Curran MA; Yu D; Han L; Darabi R; Yang L; Moslehi JJ; Lin C
Sci Transl Med; 2022 Nov; 14(669):eabo1981. PubMed ID: 36322628
[TBL] [Abstract][Full Text] [Related]
50. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A
Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899
[TBL] [Abstract][Full Text] [Related]
51. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
[TBL] [Abstract][Full Text] [Related]
52. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
53. C-X-C Motif Chemokine Ligand 9 Correlates with Favorable Prognosis in Triple-Negative Breast Cancer by Promoting Immune Cell Infiltration.
Cao X; Song Y; Wu H; Ren X; Sun Q; Liang Z
Mol Cancer Ther; 2023 Dec; 22(12):1493-1502. PubMed ID: 37669562
[TBL] [Abstract][Full Text] [Related]
54. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
55. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
56. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
[TBL] [Abstract][Full Text] [Related]
57. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
[TBL] [Abstract][Full Text] [Related]
58. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
59. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
60. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]